France is home to more than 65 million people and 80% of the population lives in urban areas. Thanks to well-developed health structures and vaccination programs, the infant survival rate in France is almost equal to 100%. In 2017, the infant survival rate was 759 out of 761. The main diseases reported in the country are measles and whooping cough. In 2017, according to WHO, reported cases of measles increased to 520 in 2017 from 80 in 2016. The number of pertussis cases increased from 155 to 56 in 2016. No cases were reported for mumps, polio, rubella, tetanus (neonatal) and tetanus (total) during the period 2012-2016. Total vaccination coverage in France is close to 90%. In 2017, DTP1 vaccination was 99%, DTP3 was 96% and HepB3 was 90%. According to the WHO, the main vaccines planned in the country were BCG, diphtheria, DTaP, hepatitis A, hepatitis B and shingles, among others.
The market is segmented by type, application and technology. Depending on the type, the market is segmented into animal DNA vaccine and human DNA vaccine. Depending on the application, the market is segmented in oncology, infectious diseases and others. Based on the technology, the market is segmented into plasmid DNA vaccine and delivery of plasmid DNA.
The main market players active in the market are Eli Lilly and Co., GE Healthcare, GlaxoSmithKline PLC., Inovio Pharmaceuticals Inc., Merck & Co., Novartis AG, Pfizer Inc., Roche Diagnostics GMBH and Sanofi Inc. players contribute significantly to market growth through the adoption of various strategies, including the launch of new products, mergers and acquisitions, collaborations with the government, financing of start-ups and technological advances to remain competitive on the market.
This report provides an in-depth analysis of the size of the market, the expected quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market, integrating various models in depth.
Research and analysis of the DNA vaccine market in France by type
Study and analysis of the DNA vaccine market in France by technology
Study and analysis of the DNA vaccine market in France by application
The report covers
Complete research methodology for the French DNA vaccine market.
A detailed and complete overview of the market with key information on analysts.
A comprehensive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the French DNA vaccine market.
Overview of the market determinants which stimulate the French market for DNA vaccines.
Detailed and extensive market segments with regional distribution of expected revenues.
Extensive profiles and recent developments of market players.
Key topics covered:
1. Summary of the report
1.1. Research methods and tools
1.2. Market breakdown
1.2.1. By segments
2. Market overview and outlook
2.1. Scope of the report
2.2. Overview of analysts and current market trends
2.2.1. Key Findings
2.3. Rules and Regulations
3. Competitive landscape
3.1. Competitive share analysis
3.2. Analysis of the key strategy
3.3. Analysis of the key company
3.3.2. Financial analysis
3.3.3. SWOT analysis
3.3.4. Recent DEVELOPMENTS
4. Market determinants
5. Market segmentation
5.1. France’s DNA vaccine market by type
5.1.1. Animal DNA vaccine
5.1.2. Human DNA vaccine
5.2. France DNA vaccine market by technology
5.2.1. Plasmid DNA vaccine
5.2.2. Plasmid DNA delivery
5.3. France’s DNA vaccine market by application
5.3.2. Infectious disease
6 Company profiles
6.1 Eli Lilly and Co.
6.2 GE Healthcare
6.3 Glaxosmithkline PLC.
6.4 Inovio Pharmaceuticals Inc.
6.5 Merck & Co.
6.6 Novartis AG
6.7 Pfizer Inc.
6.8 Roche Diagnostics GMBH
6.9 Sanofi Inc.
For more information on this report, visit https://www.researchandmarkets.com/r/q4sume.
ResearchAndMarkets.com is the world’s leading source for market research reports and international market data. We provide you with the latest data on international and regional markets, key industries, best companies, new products and the latest trends.